Clinical Trial Update: Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 study of TAS3681 in metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• TAS3681 (TAS-3681)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 1 | Status: COMPLETED